Cornea/External Disease News

As I amble across the dry eye disease landscape, I come across all manner of things that are just not quite ready for prime time.

Stuart Therapeutics has completed patient enrollment in a phase 2 clinical trial of ST-100 for the treatment of dry eye disease.

EyeGate Pharmaceuticals has completed enrollment in a phase 2 proof-of-concept study investigating PP-001 in patients with ocular surface inflammation, according to a press release.

The first patient has been enrolled in a phase 4 clinical trial to evaluate the safety and efficacy of Tepezza in patients with chronic thyroid eye disease, according to a press release from Horizon Therapeutics.

Corneal cross-linking and the potential of robotics are the topics of the best performing cover stories so far in 2021.

Corneal neurotization, a sensory nerve transplant procedure, can restore corneal sensation in insensate corneas and improve visual acuity.

AXR-270 demonstrated "statistically and clinically meaningful improvement" in patients with dry eye disease associated with meibomian gland dysfunction, according to a press release from AxeroVision.

Phase 3 study results of a presbyopia drop and discussions about dry eye disease treatments topped videos from the American Society of Cataract and Refractive Surgery meeting held in Las Vegas earlier this summer.

Fluctuating dry eye symptoms following surgery or exposure to environmental triggers are “highly suggestive” of flares, according to a poster presented at the Women in Ophthalmology Summer Symposium.

LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, AnnMarie Hipsley, DPT, PhD, discusses microporation therapeutics and its potential role in presbyopia treatment.